公开(公告)号：US06586003B2

公开(公告)日：2003-07-01

申请号：US10038417

申请日：2002-01-02

申请人： Dexi Liu ,  Feng Liu ,  Jing-Ping Yang ,  Leaf Huang

发明人： Dexi Liu ,  Feng Liu ,  Jing-Ping Yang ,  Leaf Huang

IPC分类号： A61K927

CPC分类号： A61K9/1075 ,  Y10S514/938

摘要： New emulsion and micelle formulations are described as are complexes of these formulations with biologically active substances. The novel formulations are different from cationic lipid vectors such as cationic liposomes in that the complexes formed between biologically active substances and the emulsion and micellar formulations of this invention are physically stable and their transfection activity is resistant to the presence of serum. These novel formulations are disclosed to be useful in areas such as gene therapy or vaccine delivery.

公开(公告)号：US5043164A

公开(公告)日：1991-08-27

申请号：US298452

申请日：1989-01-17

申请人： Leaf Huang ,  Dexi Liu

发明人： Leaf Huang ,  Dexi Liu

IPC分类号： A61K9/127 ,  A61K9/133

CPC分类号： A61K9/1275 ,  A61K9/127 ,  Y10S436/829 ,  Y10S514/97 ,  Y10S514/971 ,  Y10T428/2984

摘要： Small unilamellar liposomes (d

摘要翻译： 通过向新制备的脂质体悬浮液中加入包含不饱和磷脂酰乙醇胺（PE）如二油酰PE（DOPE）和脂肪酸如油酸（OA）的小单层脂质体（d <600nm）），其具有 形成胶束的高趋势。 示出了以下胶束形成两亲物的实例：溶血磷脂，神经节苷脂（GM1和GT1b），硫苷脂，合成糖脂如唾液酸乳糖基磷脂酰乙醇胺，亲水药物如胞嘧啶阿拉伯糖二磷酸二甘油，和蛋白质如细胞色素b5，人高密度 脂蛋白（HDL）和人血型糖蛋白A。稳定的脂质体对白蛋白的溶解作用有抗性，白蛋白是导致这种脂质体裂解的主要血液成分。 在本发明之前，包含PE和OA的脂质体通常通过掺入胆固醇来稳定。

公开(公告)号：US6120794A

公开(公告)日：2000-09-19

申请号：US534180

申请日：1995-09-26

申请人： Dexi Liu ,  Feng Liu ,  Jing-Ping Yang ,  Leaf Huang

发明人： Dexi Liu ,  Feng Liu ,  Jing-Ping Yang ,  Leaf Huang

IPC分类号： A61K9/107 ,  A61K31/70 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K47/18 ,  A61K47/24 ,  A61K48/00 ,  A61K9/127

CPC分类号： A61K9/1075 ,  Y10S514/938

摘要： New emulsion and micelle formulations are described as are complexes of these formulations with biologically active substances. The novel formulations are different from cationic lipid vectors such as cationic liposomes in that the complexes formed between biologically active substances and the emulsion and micellar formulations of this invention are physically stable and their transfection activity is resistant to the presence of serum. These novel formulations are disclosed to be useful in areas such as gene therapy or vaccine delivery.